Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.
Leisha A. Emens, MD, PhD
Advertisement
Articles by Leisha A. Emens, MD, PhD
Leisha A. Emens, MD, PhD, discusses the combination of checkpoint inhibitors and PARP inhibitors in ovarian cancer.
Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Emens on the Future of Immunotherapy in Ovarian CancerPublished: December 23rd 2019 | Updated:
Dr. Emens on Combining Checkpoint Inhibitors With PARP Inhibitors in Ovarian CancerPublished: February 21st 2020 | Updated:
Dr. Emens on Immune-Related Adverse Events in Ovarian CancerPublished: March 4th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5